학술논문
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
Document Type
Article
Author
Pigeon-Kherchiche, Patricia; Flaus-Furmaniuk, Anna; Bald, Martin; Denzer, Christian; von Schnurbein, Julia; Abawi, Ozair; Blume-Peytavi, Ulrike; Krabusch, Philipp; Mai, Knut; Schnabel, Dirk; Wiegand, Susanna; Flück, Christa E; Schulz, Esther; Voss, Egbert; Bratina, Natasa; Weiss, Katja; Martos-Moreno, Gabriel Á; Danset, Alban; Gougis, Paul; Dubern, Béatrice; Clément, Karine; van den Akker, Erica L.T.; Argente, Jesús; Bahm, Allison L; Chung, Wendy K; Connors, Hillori S; De Waele, Kathleen; Farooqi, Ismaa Sadaf; Gonneau-Lejeune, Julie; Gordon, Gregory A; Poitou, Christine; Puder, Lia; Swain, James M; Stewart, Murray W; Yuan, Goujun; Wabitsch, Martin; Kühnen, Peter; van den Akker, Erica ; Bahm, Allison; Connors, Hillori; Farooqi, I Sadaf; Gordon, Gregory; Kohlsdorf, Katja; Swain, James; Stewart, Murray; Yuan, Guojun
Source
In The Lancet Diabetes & Endocrinology December 2020 8(12):960-970
Subject
Language
ISSN
2213-8587